Aug 13, 2018 Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma Learn More
Aug 10, 2018 Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update Learn More
Jul 31, 2018 Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Learn More
Jul 27, 2018 Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering Learn More